rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone + thiotepa + dexamethasone

This treatment regimen combines standard systemic immunochemotherapy (typically R-CHOP) with intrathecal (IT) administration of thiotepa and dexamethasone for central nervous system (CNS) prophylaxis. It is specifically designed for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are at high risk for CNS relapse, such as those with a CNS-IPI score of 4 or higher, dual protein expression, or involvement of high-risk organs. Thiotepa is a polyfunctional alkylating agent that, along with its active metabolite tepa, demonstrates high CNS bioavailability, making it an effective agent for preventing secondary CNS involvement. Dexamethasone is a synthetic glucocorticoid used in this context to reduce inflammation and potentially enhance the efficacy of the prophylaxis. The regimen is being evaluated in a Phase II clinical trial led by Zhejiang Cancer Hospital to assess its efficacy in reducing CNS recurrence rates and its overall safety profile in high-risk populations.

Other names

R-CHOP + thiotepa + dexamethasoneR-CHOP plus IT thiotepa and dexamethasoneIntrathecal Thiotepa for CNS Prophylaxis in High-risk DLBCL